{rfName}
Cl

Indexed in

Citations

35

Altmetrics

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Marrupe, DAuthorMartinez-Amores, BAuthor

Share

January 23, 2023
Publications
>
Article
No

Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting

Publicated to: Clinical & Translational Oncology. 23 (4): 812-819 - 2021-01-01 23(4), DOI: 10.1007/s12094-020-02473-w

Authors:

Franco, F; Camara, J C; Martin-Valades, J, I; Lopez-Alfonso, A; Marrupe, D; Gutierrez-Abad, D; Martinez-Amores, B; Leon, A; Juez, I; Perez, M; Royuela, A; Ruiz-Casado, A
[+]

Affiliations

Fdn Hosp Alcorcon, Dept Med Oncol, Alcorcon, Spain - Author
Fdn Jimenez Diaz, Dept Med Oncol, Madrid, Spain - Author
Hosp Univ Fuenlabrada, Dept Med Oncol, Fuenlabrada, Spain - Author
Hosp Univ Infanta Leonor, Dept Med Oncol, Madrid, Spain - Author
Hosp Univ Mostoles, Dept Med Oncol, Mostoles, Spain - Author
Hosp Univ Puerta de Hierro, Dept Biostat, Majadahonda, Spain - Author
Hosp Univ Puerta de Hierro, Dept Med Oncol, Majadahonda, Spain - Author
Hosp Univ Rey Juan Carlos, Dept Med Oncol, Mostoles, Spain - Author
See more

Abstract

Background/objectives The incidence of pancreatic cancer is increasing in developed countries. The incorporation of new therapies, to the first-line treatment of patients with good performance status led to better survival in clinical trials. However, there is a wide variability in their use and some concerns about the treatment of elderly patients who were not included in the clinical trials. Methods This is a retrospective multicenter study. Data from consecutive patients diagnosed with metastatic pancreatic cancer (mPC) treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) were analysed to evaluate efficacy (overall survival-OS) and toxicity. Results A total of 119 patients were included. 49.6% were treated with FFX and 50.4% with GNP in first-line. The median OS was 12 months with no statistically significant differences between both regimens (12.7 m for FFX vs 10.2 m for GnP). Elevated Ca 19.9 levels and neutrophil-lymphocyte ratio (NLR) increased the risk of death. Patients who received both regimens in first/second line had a median OS longer than 15 months whichever the sequence. 32 patients (27%) were older than 70-y. 54% patients received a second-line treatment, 56% in the FFX group and 44% in the GnP group. The median OS for patients older than 70 was 9.5 m versus 12.3 m for patients younger than 70. Progression of the disease was the cause of death in 67.6% of the patients. Conclusions In our setting, the use of FFX and GnP for treating mPC is quite similar, but superiority could not be demonstrated for any of the schemes in the first line. OS was determined by basal levels of Ca 19.9 and NLR. Patients receiving both regimens in first/second line whichever the sequence, exhibited the best survival rates. In our series, elderly patients had poorer survival rates.
[+]

Keywords

AdultAge factorsAgedAged, 80 and overAntineoplastic combined chemotherapy protocolsCause of deathChemotherapyDeoxycytidineDisease progressionFemaleFluorouracilFolfirinoxGemcitabineHumansIrinotecanLeucovorinMaleMetastatic pancreatic cancerMiddle agedOverall survivalOxaliplatinPaclitaxelPalliative carePancreatic neoplasmsRetrospective studiesSurvivalSurvival rateToxicity of treatmentTrendsZero hunger

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Clinical & Translational Oncology due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position , thus managing to position itself as a Q2 (Segundo Cuartil), in the category Medicine (Miscellaneous). Notably, the journal is positioned en el Cuartil Q3 for the agency WoS (JCR) in the category Oncology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-16:

  • WoS: 13
  • Scopus: 11
  • Europe PMC: 8
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 17.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 17 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 9.
  • The number of mentions on the social network X (formerly Twitter): 14 (Altmetric).
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 2 - End hunger, achieve food security and improved nutrition and promote sustainable agriculture, with a probability of 44% according to the mBERT algorithm developed by Aurora University.
[+]

Project objectives

Los objetivos perseguidos en esta aportación fueron analizar la eficacia y toxicidad de los tratamientos FOLFIRINOX (FFX) y gemcitabina más nab-paclitaxel (GnP) en pacientes con cáncer pancreático metastásico en un contexto real; evaluar la supervivencia global (OS) y su relación con los niveles basales de Ca 19.9 y la ratio neutrófilo-linfocito (NLR); determinar el impacto del uso secuencial de ambos regímenes en primera y segunda línea sobre la supervivencia; caracterizar la variabilidad en el uso de estos tratamientos, especialmente en pacientes mayores de 70 años; y comparar la supervivencia entre pacientes mayores y menores de 70 años para identificar diferencias clínicas relevantes.
[+]

Most relevant results

El estudio evaluó la eficacia y toxicidad de FOLFIRINOX (FFX) y gemcitabina más nab-paclitaxel (GnP) en pacientes con cáncer pancreático metastásico en un entorno real. Los resultados principales fueron: la mediana de supervivencia global (OS) fue de 12 meses sin diferencias significativas entre FFX (12.7 meses) y GnP (10.2 meses); niveles elevados de Ca 19.9 y la relación neutrófilo-linfocito (NLR) aumentaron el riesgo de muerte; pacientes que recibieron ambos tratamientos en primera y segunda línea mostraron una OS superior a 15 meses independientemente de la secuencia; el 27% de los pacientes tenían más de 70 años, con una OS mediana de 9.5 meses frente a 12.3 meses en menores de 70; el 67.6% falleció por progresión de la enfermedad.
[+]